This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com
by Zacks Equity Research
Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com
Bet On 5 Stock Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition
by Zacks Equity Research
Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.
Medidata Cloud Manages Echocardiogram Images in WASE Study
by Zacks Equity Research
Medidata's (MDSO) Rave Imaging platform is a cloud-based clinical data management system used to electronically capture, manage and report clinical research data.
Here's Why You Should Hold CONMED Stock in Your Portfolio
by Zacks Equity Research
Despite aggressive rivalry in the MedTech space, CONMED (CNMD) to gain from its unique offerings and an extensive product portfolio.
Here's Why You Should Buy HealthEquity (HQY) Stock Right Now
by Zacks Equity Research
Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.
Can Inogen (INGN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Inogen (INGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength?
by Zacks Equity Research
Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INGN) Outperforming Other Medical Stocks This Year?
Stryker's HyperBranch Buyout to Boost Neurotechnology Business
by Zacks Equity Research
Stryker's (SYK) craniomaxillofacial division's market prospects bright.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
by Zacks Equity Research
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
Looking for Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks may surpass bottom-line estimates in their next release.
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
Inogen (INGN) Up 14.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Inogen (INGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) gains from strong Q2 results and bright global prospects.
Can Inogen (INGN) Stock Continue to Grow Earnings?
by Zacks Equity Research
Inogen (INGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
by Zacks Equity Research
Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Align Technology International Growth Solid, Rivalry Rife
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.
Why You Should Add Chemed (CHE) Stock to Your Portfolio Now
by Zacks Equity Research
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
DaVita Healthcare Partners' New Facility Now in Los Angeles
by Zacks Equity Research
DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Masimo (MASI) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.